Ron Fitzmartin,
PhD
Senior Advisor, Strategic Programs,Center for Drug Evaluation and Research, US Food and Drug Administration
Dr. Fitzmartin is Senior Advisor in the Center for Drug Evaluation and Research’s Office of Strategic Programs, focusing on policy and guidance related to data standards and electronic submissions. In addition, Ron chairs this Center’s Operations Committee for Data Standards, the Electronic Submission Gateway Board, and the Prescription Drug User Fee Act Informatics Group. Prior to joining the US Food and Drug Administration, Ron served as Vice President, Informatics at Daiichi Sankyo, Inc.; Vice President, Biostatistics and Data Management at Daiichi Medical Research, Inc.; and as Executive Director, Biostatistics and Data Management at Purdue Pharma L.P. Dr. Fitzmartin received his PhD from the University of Maryland, his MBA from the University of New Haven, and an MS/BS from Southern Connecticut State University.
Fellows of DIA
-
Tatsuo Kurokawa,
PhD •Chair, Fellows of DIA
President, Japan Self-Medication Industry -
Martin Harvey Allchurch • Principal International Affairs Officer, European Medicines Agency, European Union
-
Minnie Baylor-Henry,
JD • President, B-Henry & Associates -
Gaby Danan,
MD, PhD • Pharmacovigilance Expert -
Richard Day,
MD • Professor of Clinical Pharmacology, St. Vincent's Hospital -
Marie Dray,
MBA • President, International Regulatory Affairs Group LLC -
Nancy A. Dreyer,
MPH, PhD • Global Chief, Sci Affairs; Sr VP, Head, Center for Advanced Evidence Generation
IQVIA -
Ron Fitzmartin,
PhD • Senior Advisor, Strategic Programs,Center for Drug Evaluation and Research, US Food and Drug Administration -
E. Stewart Geary,
MD • Senior VP, Chief Medical Officer, Director, Corporate Medical Affairs HQ, Eisai Co., Ltd. -
Ken Getz,
MBA • Chairman, CISCRP; Director of Sponsored Research, Tufts Center For the Study of Drug Development -
Alberto Grignolo,
PhD • Corporate Vice President
PAREXEL International -
Yves Juillet,
MD • Senior Vice-President, Industrie Sante -
Sandra L. Kweder,
MD • Deputy Director, FDA Liaison to the EMA, Office of International Programs, OC -
Murray M. Lumpkin,
MD • Deputy Director, Integrated Delivery, and Lead for Global Regulatory Systems Initiatives
Bill and Melinda Gates Foundation -
Sandra A. Milligan,
MD, JD • Senior Vice President, Head of Global Regulatory Affairs and Clinical Safety, Merck & Co., Inc. -
Noriaki Murao,
MS • Representative, NM Consulting -
Jennifer Riggins,
PhD • Advisor, Digital Channels and eCapabilities, Eli Lilly and Company -
Jeffrey Sherman,
MD • Chief Medical Officer & EVP, Horizon Pharma, Inc. -
Per Spindler,
DVM, MBA • Director Biopeople, University of Copenhagen -
Ling Su,
PhD • Professor and Director, Institute of Drug Regulatory Science, Shenyang Pharmaceutical University, Venture Partner, Lilly Asia Ventures